Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Analyst
Larry Solow
Period: Reporting periods mapped to calendar 2024 Q4 – 2026 Q1 (6 quarters; questions recorded in 5).
- Questions
- 10on tracked calls
- Challenge rate
- 0%none of 10 questions
- Companies
- 1questioned at least once
- Reporting periods
- 5with questions
These figures cover the whole profile: every tracked question, all reporting periods.
How to read these numbers
Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.
Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.
No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.
Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.
Small samples. Profiles with fewer than 10 questions are marked Limited sample.
Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.
Questions asked
Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.
Showing 10 of 10 questions from 1 company
WSTWest Pharmaceutical Services10 questions · 5 reporting periods · 0 of 10 challenging
Calendar 2026 Q1
It sounds like nothing imminent, but just curious how the search is going?
Show response
Eric confirmed active CEO search with appointment expected in second half of 2026.
should we expect for the rest of the year, do we expect a little bit of a dip?
Show response
Bob confirmed front-half weighting with Q3 as trough. Drug handling $20M mostly in back half, replacing CGM at roughly 2x gross margin. Drug handling peak revenue is roughly 3x the 2026 level, ramping through 2027.
what folks are kind of shifting towards? Is it more towards the lower end of the curve
Show response
Eric explained Annex-1 conversions are a mix, with weighted average around Westar/Envision level. Some go to high-end HVP including NovaPure. Also seeing shifts from lower HVP to higher end. All positive for revenue and margins.
Calendar 2025 Q3
Just curious if you guys are actually seeing, and I think this has been part of the team too, just an improvement in mix within HVP
Show response
Bob confirmed positive mix within HVP from higher-ASP products plus fixed-cost leverage from filling installed capacity. Cited scrap, yield improvements, raw material sourcing, and production streamlining as additional multiyear margin drivers.
Calendar 2025 Q2
I think underlying SG&A, it looks like it was up like 16%. I know that moves around a little bit quarter-to-quarter
Show response
Bernard attributed SG&A increase to FX impact from the euro-dollar rate movement, with nothing else specific to call out.
Is that translating into actual revenue growth so fast or a lot of these clients. Can you just give us kind of a little more color
Show response
Eric confirmed 150 basis points expected from Annex-1 in 2025, noting projects take multiple quarters through validation before commercialization. Strong momentum with variation by client.
Calendar 2025 Q1
do you see any real significant impact outside of some of the direct tariff impacts, but just on demand
Show response
Eric said no demand impact from macro or government spending changes, noting visible increase in demand consistent with prior quarter commentary.
Is that purely a function of the timing you mentioned and discussed inventory destocking?
Show response
Bernard cited lighter pricing and a facility constraint from a customer switching product demand into one plant as additional factors beyond destocking.
Calendar 2024 Q4
just maybe a little tease on where the, you know, the incremental opportunities not included in guidance
Show response
Eric declined to size opportunities specifically but expressed confidence in HVP components and team execution, leaving the range unchanged.
it sounds like the core HVP is doing okay, but there will be a little bit of a transition on SmartDose
Show response
Eric provided comprehensive breakdown of HVP drivers: biologics at 90% win rate, GLP-1 long-term contract, Annex One converting 50% of 200+ projects in 2025.
Challenge rate by company
Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.
| Company | Questions | Challenge rate |
|---|---|---|
| WST West Pharmaceutical Services | 10 | 0%none of 10 questions |
- WSTWest Pharmaceutical Services · 10 questions0%none of 10 questions
Activity by reporting period
Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.
| Calendar period | Questions | Challenge rate | Companies |
|---|---|---|---|
| 2024 Q4 | 2 | 0%none of 2 questions | 1 |
| 2025 Q1 | 2 | 0%none of 2 questions | 1 |
| 2025 Q2 | 2 | 0%none of 2 questions | 1 |
| 2025 Q3 | 1 | 0%none of 1 question | 1 |
| 2025 Q4 | No questions recorded | — | — |
| 2026 Q1 | 3 | 0%none of 3 questions | 1 |
- 2024 Q42 questions · challenge rate 0% (none of 2 questions) · 1 company
- 2025 Q12 questions · challenge rate 0% (none of 2 questions) · 1 company
- 2025 Q22 questions · challenge rate 0% (none of 2 questions) · 1 company
- 2025 Q31 question · challenge rate 0% (none of 1 question) · 1 company
- 2025 Q4No questions recorded
- 2026 Q13 questions · challenge rate 0% (none of 3 questions) · 1 company
Topics
Topics tagged on this analyst’s questions.
- Margin5
- Revenue Growth5
- Capital Allocation2
- Regulation Policy2
- Competitive Dynamics1
- Cost Pressure1
- Macroeconomic1
- Demand1
- Supply Chain1
- Guidance Reliability1